Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographics and clinical characteristics of the 56 patients, categorized by responders and non-responders

From: Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

Characteristics All patients
(n = 56)
Respondersa
(n = 8)
Non-responders
(n = 48)
P value
Sex Male 31 (55%) 5 26 0.72
Female 25 (45%) 3 22
Age (years) Median (range) 65 (43–91) 62 (44–74) 65 (43–91) 0.29
Race White 49 (88%) 8 41 1.00
Black 3 (5%) 0 3
Asian 2 (3.5%) 0 2
Other 2 (3.5%) 0 2
Smoking Never 10 (18%) 1 9 1.00
Former 27 (48%) 4 23
Current 19 (34%) 3 16
Histology Adenocarcinoma 40 (71%) 6 34 0.59
Squamous cell carcinoma 9 (16%) 2 7
NSCLC NOSb 7 (13%) 0 7
  1. airRECIST1.1 and RECIST1.1 have resulted in the same 8 responders
  2. bNSCLC NOS = non-small-cell carcinoma not otherwise specified